650
Participants
Start Date
December 2, 2013
Primary Completion Date
November 20, 2017
Study Completion Date
June 30, 2018
Bevacizumab
5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
CPT-11 (Irinotecan)
150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
5-FU Bolus
400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
5-FU Infusion
2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
l-LV (dl-LV)
200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
bevacizumab
7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.
CPT-11 (Irinotecan)
150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.
Capecitabine
1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
NPO Epidemiological and Clinical Research Information Network (ECRIN), Kyoto
Epidemiological and Clinical Research Information Network
OTHER